The clinical trial covered 18 patients with Alzheimer’s who have been dealing with agitation symptoms. The study found that SCI-110 met its primary endpoints of safety and efficiency with dosing twice a day. It also did so without showing side effects for the patients.
Dr. Adi Zuloff- Shani, Chief Technologies Officer of SciSparc, said the following about the clinical trial results:
“We are thrilled with these outcomes, as they signify a monumental potential in enhancing the lives of AD patients. Our commitment to pioneering innovative treatments with a global impact has never been clearer.”
What’s Next for SPRC Stock?
With this positive clinical trial data under its belt, it’s likely that SciSparc will continue the development of SCI-110. That means more clinical trials, as well as the possibility of the drug getting commercial approval.
These possibilities have investors in SPRC stock excited today, which explains the 46.6% increase as of this writing. It also gives a reason for the more than 9 million shares changing hands today. That’s already well above the company’s daily average trading volume of about 1.2 million shares.
Investors who are searching for even more of the most recent stock market stories are going to want to stick around!
We have all of the biggest stock market news that traders need to know about on Wednesday! A few examples include what’s happening with stocks rising today, as well as the latest news concerning Manchester United (NYSE:MANU) and C3.ai (NYSE:AI) stock. All of that is ready to go at the links below!
More Wednesday Stock Market News
- Why Are Stocks Up Today?
- MANU Stock Alert: What to Know as Manchester United CEO Steps Down
- AI Stock Alert: C3.ai Expands AI Partnership With Amazon
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.